Therapeutically, supplementing miR-181d-5p in A-T cells (where it is deficient) while inhibiting over expressed miR-181a/b (and related family members) in cancers that still retain some ATM activity is the best possible approach because the two settings show opposite miR-181 family dysregulation and thus require opposite interventions. The gene discussed is ATM; the disease is cancer.